Is ORKA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on ORKA-001 efficacy and dosing differentiation, with revenue (ttm) at ~$0 (pre-revenue). The bear case rests on oRKA is a pre-revenue, clinical-stage biotech, so failure of a registrational trial or a safety signal could cause severe and permanent loss of value. Analysts covering it are spread from $117.00 to $200.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. ORKA is a pre-revenue, clinical-stage biotech, so failure of a registrational trial or a safety signal could cause severe and permanent loss of value. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $117.00, +62.7% from the $71.93 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

ORKA-001 efficacy and dosing differentiation. The lead IL-23p19 antibody posted strong interim Phase 2a skin-clearance rates and is engineered for potential once-yearly dosing. The most optimistic analyst target on ORKA is $200.00, +178.0% from the $71.93 price. That figure is only reachable if this thesis works close to its best case.

ORKA is a pre-revenue, clinical-stage biotech, so failure of a registrational trial or a safety signal could cause severe and permanent loss of value. Interim Phase 2a results do not guarantee success in larger, longer registrational studies, and the psoriasis space is intensely competitive with established, effective biologics from much larger companies. The valuation already embeds substantial clinical optimism: the stock fell on positive Week 28 data, which shows how little upside surprise strong results now carry, and it dropped ~24% in the month to October 16, 2026. Insider share sales in September and October 2026 add to the sentiment overhang. The company burns tens of millions of dollars per quarter and will likely need additional capital over time, which can dilute shareholders. The stock has been highly volatile, with a 52-week range of ~$25 to ~$116. The most pessimistic published target is $117.00, +62.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Oruka Therapeutics is a clinical-stage biopharmaceutical company developing novel monoclonal antibodies for plaque psoriasis and other inflammatory and immunology conditions.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (ORKA-001 efficacy and dosing differentiation) stalling in the reported numbers rather than in the narrative, the risk above (oRKA is a pre-revenue, clinical-stage biotech, so failure of a registrational trial or a safety signal could cause severe and permanent loss of value) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Oruka is a clinical-stage biotech developing half-life-extended monoclonal antibodies for plaque psoriasis and other inflammatory conditions. Its goal is best-in-class efficacy with far less frequent dosing than existing biologics. It has about 68 employees.

No. Oruka is pre-revenue and generates no product sales. It runs at a net loss (~$110 million over the twelve months to June 2026) and funds its trials from cash raised through equity offerings, which is typical for a clinical-stage biotech.

ORKA-001 is Oruka's lead drug, a half-life-extended IL-23p19 antibody for moderate-to-severe plaque psoriasis. It is designed for potential once-yearly dosing. In the EVERLAST-A Phase 2a trial, 71.4% of treated patients reached PASI 100 at Week 28, up from 63.5% at Week 16, with no doses given after Week 4.